Open Nav

Onconova Therapeutics, Inc.

  • Ramesh Kumar, Onconova Therapeutics, Inc.

expand awareness of Rigosertib and pre-clinical assets

  • Date:Thursday, October 18
  • Time:11:00 AM - 11:15 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova is currently enrolling patients in a pivotal Phase 3 trial testing its lead compound, rigosertib, in patients with myelodysplastic syndromes (MDS). Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages.
  • Company Website:www.onconova.com
  • Company HQ City:Newtown
  • Company HQ Country:United States
  • Company HQ State:Pennsylvania           
  • Ticker:ONTX
  • Exchange:Nasdaq
  • CEO/Top Company Official:Ramesh Kumar
  • Year Founded:1998
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Rigosertib
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:COMPANY HIGHLIGHTS Targeting underserved market in Myelodysplastic Syndromes (MDS): >10,000 patients diagnosed annually in the U.S. with Higher-risk (HR) MDS; No new approved treatments in over 10 years *Rigosertib partnered with SymBio in Japan/Korea and with Pint Pharma in Latin America *Patents & Orphan Designation for MDS in the US, Europe and Japan *Collaborative program with NCI in RASopathies, rare diseases of children *Designing Phase 3 trial for Oral rigosertib + azacitidine combination: Targeting larger first-line patient population for higher risk MDS *CDK 4/6+ARK5 Inhibitor program - IND process and start of Phase 1 program; partnered with HanX for greater China; new alliances being sought *Key milestones ahead: 1) Phase 3 INSPIRE trial progressing to completion after promising interim analysis and enhanced powering; Trial completion projected in H1-2019 2) Combination trial for front-line high risk MDS ready to advance to Phase 3 in H2-2018
Speakers
Ramesh Kumar
Onconova Therapeutics, Inc.
Back